Lexology February 18, 2021
Nossaman LLP

Congress and the Biden Administration are grappling with an economic stimulus bill that will touch many segments of American life, including health care, if it passes in the Senate. This has many clients wondering what impact the Biden Administration will have on the healthcare sector from a regulatory perspective. Early indications point to a focus on four issues that continue to resound: the Affordable Care Act (“ACA”), COVID-19-related regulatory relief, lowering prescription drug prices and restricting the occurrence of surprise billing.

The ACA

To strengthen the ACA, the Biden Administration has proposed three key steps: (1) capping the amount each household spends on insurance premiums at 8.5% of household income; (2) increasing subsidies to low-income Americans; and (3) initiating an...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: ACA (Affordable Care Act), Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Insurance, Medicaid, Payer, Pharma, Pharma / Biotech, Pricing / Spending, Public Exchange, Public Health / COVID
Medicare Telehealth, Hospital-at-Home Flexibilities In Danger As Partial Government Shutdown Threat Rises
Federal Discretionary Spending To Address Substance Use Disorders: How Big A Shift?
White House and Congress Turn Focus to Health Policy
CVS accused of shutting out rival pharmacy hubs in House Judiciary investigation
OIG Recounts Historic Recovery Numbers in Its Latest Semiannual Report to Congress

Share Article